Five Biotech Events to Watch in 2010
Our senior biotech columnist offers his picks for the five biggest stock-moving events for 2010.
10:23AM 12/16/09
Biotech Calendar: Upcoming FDA Dates
A quick and dirty guide to the expected regulatory news from the FDA through June 2010.
04:25PM 12/14/09
Human Genome's CEO: Biotech's Best '09
Human Genome Science's CEO Thomas Watkins is Adam Feuerstein's Best Biotech CEO of the Year for 2009.
11:50AM 12/14/09
Dendreon Announces Exercise Of Option By Underwriters In Its Common Stock Offering
06:13PM 12/11/09
Dendreon Names Hans Bishop Chief Operating Officer
Dendreon names former Bayer executive Hans Bishop chief operating officer
08:08AM 12/10/09
Dendreon Appoints Hans Bishop As Chief Operating Officer
- Seasoned Global Oncology Executive Joining Team, Expanding Company's Commercial Expertise -
06:30AM 12/10/09
Cel-Sci's History of Disappearing Drugs: BioBuzz
Will Cel-Sci's flu drug last longer than its other fly-by-night projects?
09:20AM 11/24/09
BioCryst Bull Blames Conspiracy for Stock's Fall: BioBuzz
Hedge funds, Wall Street, SEC and FDA out to hurt maker of flu drug, newsletter writer claims.
06:45AM 11/24/09
Dendreon's Provenge Gets FDA Review Date
Dendreon's potential prostate cancer treatment Provenge gets May 1 FDA review date
10:54AM 11/20/09
Dendreon Receives FDA Acknowledgement Of Complete Response
-- PDUFA Date Assigned as May 1, 2010 --
08:30AM 11/20/09
Biotech Stock Mailbag: FDA Playbook
Smart drug and biotech companies keep the FDA abreast of their clinical trial program throughout the long drug-development process.
06:01AM 11/20/09
So far, it is just some mild consolidation after a big day yesterday.
10:29AM 11/17/09
Spectrum Posts Encouraging Zevalin Sales: BioBuzz
Also, Dendreon's FDA Date Set for April 30, 2010.
08:44AM 11/12/09



Connect with TheStreet